// App-Quantinova.ai

1059 : Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

Researchers

Presenter

  • Sara M. Tolaney

Principal Investigators

  • Peter Kabos

  • Maura N. Dickler

  • Luca Gianni

  • Valerie Jansen

  • Yi Lu

  • Suzanne Young

  • Hope S. Rugo

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Colorado Denver, Greenwood Village, CO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • San Raffaele Hospital, Milan, Italy

  • Eli Lilly and Company, Indianapolis, IN

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

  • Italy

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pembrolizumab

  • Abemaciclib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • NCT02079636

  • NCT02779751

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved